GSK PLC SEC Filings

GSK plc files a Form 6-K reporting a TR-1 notification that a major holder has 4.930000% of its voting rights, representing 200,296,898 voting rights in total. These are held through ordinary shares and ADRs, with no additional voting rights linked to financial instruments.

The filing shows 88,958,040 voting rights (2.190000%) attached to ordinary shares and 111,338,858 voting rights (2.740000%) through ADRs, together making up the reported 4.930000% position.

GSK plc reported two senior personnel share transactions. Independent Non-Executive Director Wendy Becker purchased 4,000 Ordinary Shares at £19.6291 each on the London Stock Exchange on 2026-04-29. Ordinary Shares have a nominal value of 31¼ pence.

Chief People Officer Diana Conrad acquired 12.874 American Depositary Shares at $54.5854 per ADS under the GSK pension plan on the New York Stock Exchange on 2026-04-27. Both transactions are disclosed as initial notifications of dealings by persons discharging managerial responsibilities.

GSK reported Q1 2026 results showing steady growth driven by Specialty Medicines. Turnover reached £7.6 billion, up 5% at constant exchange rates (CER), with Specialty Medicines up 14% CER to £3.2 billion, led by HIV, respiratory and oncology products.

Core operating profit rose 10% CER to £2.65 billion, with core EPS up 9% CER to 46.5p, helped by a richer product mix, lower SG&A and higher royalty income, partly offset by increased R&D. Free cash flow was £815 million, while net debt increased to £15.6 billion following acquisitions, dividends and buybacks.

GSK declared a 17p Q1 dividend and expects a 70p dividend for 2026. The company affirmed 2026 guidance of 3–5% turnover growth and 7–9% growth in both core operating profit and core EPS at CER, and reiterated a 2031 sales outlook of more than £40 billion. GSK also highlighted multiple new product approvals, a broad late‑stage pipeline and a US agreement providing Section 232 tariff relief on patented medicines through 20 January 2029.

GSK plc reports the vesting of a 2023 Performance Share Plan award granted to its Chief Financial Officer, Julie Brown. Following performance assessment, 82% of this award vested and 18% lapsed.

The vesting delivered 243,880 Ordinary Shares at a price of £0.00 per share, including dividend equivalents, on 27 April 2026. These vested shares are subject to an additional two-year holding period. The closing price of GSK Ordinary Shares on the vesting date was £20.16.

GSK reports that the US FDA has accepted for priority review a New Drug Application for bepirovirsen, an investigational antisense oligonucleotide for adults with chronic hepatitis B. The FDA has also granted Breakthrough Therapy Designation, adding to the Fast Track Designation awarded in February 2024.

The submission is backed by phase III B-Well 1 and B-Well 2 trials, where bepirovirsen plus standard of care achieved statistically significant, clinically meaningful functional cure rates versus standard of care alone, with an acceptable safety profile. Chronic hepatitis B affects more than 250 million people worldwide, and current standard therapies usually require lifelong treatment with low functional cure rates around 1%. The FDA has assigned 26 October 2026 as the PDUFA goal date.

GSK plc reports that its investigational liver therapy efimosfermin, a once-monthly FGF21-based injection, has received US FDA Breakthrough Therapy designation and EMA PRIME status for treating metabolic dysfunction-associated steatohepatitis (MASH). These regulatory designations are intended to speed development of medicines with strong early evidence in serious diseases.

Phase II data in MASH patients with moderate to advanced (F2/F3) and cirrhotic (F4) fibrosis showed fibrosis improvement and MASH resolution versus placebo, with a generally well‑tolerated safety profile and mostly mild, transient gastrointestinal side effects. Efimosfermin is now in phase III ZENITH-1 and ZENITH-2 trials in F2/F3 patients, with additional phase III studies in F4 MASH planned this year.

MASH is described as a chronic, progressive liver disease affecting up to 5% of the global population and a leading cause of liver transplant in the US and Europe, with limited liver‑specific treatments and no approved options for cirrhotic MASH. GSK highlights efimosfermin’s potential to directly target liver fibrosis and positions it as part of a broader hepatology pipeline in MASH, chronic hepatitis B and alcohol‑associated liver disease.

GSK plc, through its subsidiary TESARO, reports a procedural update in ongoing litigation with AnaptysBio over rights to the cancer drug dostarlimab (Jemperli). The Delaware Chancery Court granted a motion by AnaptysBio to dismiss TESARO's claim for anticipatory breach. GSK notes that the ruling does not address the core contractual dispute and does not affect TESARO's remaining claim for declaratory judgment, which it plans to pursue at trial. Jemperli, the brand name for dostarlimab, is approved in over 35 countries for certain endometrial cancers, and GSK reports significant growth driven by label expansions and an ongoing clinical program in additional cancer types.

GSK plc reported a routine executive share transaction involving President Maya Martinez-Davis. She acquired notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan account. The transaction covered 8.572 ADS at a price of $55.7000 per ADS on 2026-04-22 on the New York Stock Exchange.

GSK plc reports that, on 22 April 2026, it repurchased 965,671 ordinary shares of 31¼ pence each under its existing buyback programme, acting through BNP Paribas. The shares were bought at a volume-weighted average price of 2,081.15p, with prices ranging from 2,073.00p to 2,093.00p.

The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 21,487,192 ordinary shares. After this transaction, it holds 261,378,286 shares in treasury and has 4,054,820,748 ordinary shares in issue, giving a total of 4,054,820,748 voting rights. Treasury shares represent 6.45% of voting rights, as confirmed under DTR 5.5.1R.